AVE 33.3% 0.2¢ avecho biotechnology limited

oxymorphone trials begin, page-6

  1. 5,871 Posts.
    lightbulb Created with Sketch. 17429
    The Company is preparing to re-enter the clinic to conduct a multi-dose trial with its lead product, oxycodone patch...

    Given this is the lead product, a more precise indication of when would have been nice.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.